Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences

Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences

Checkpoint inhibitor (CPI) based immunotherapy (i.e., anit-CTLA-4/PD-1/PD-L1 antibodies) can effectively prolong overall survival of patients across several cancer types at the advanced stage. However, only part of patients experience objective responses from such treatments, illustrating large indi...

Full description

Bibliographic Details
Main Authors: Xinyu Yan, Shouyue Zhang, Yun Deng, Peiqi Wang, Qianqian Hou, Heng Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-09-01
Series:Frontiers in Pharmacology
Subjects:
immunotherapy
checkpoint inhibitor
PD-1
PD-L1
CTLA-4
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2018.01050/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2018.01050/full

Similar Items